Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -47.36% is 47% below its 5-year average of -32.11%, near the low end of its 5-year range (-47.36%–-23.29%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.12% below its 12-month average of -35.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -47.36%.
RETURN ON EQUITY (ROE)
-47.36%
RETURN ON EQUITY (ROE) AVG TTM
-35.31%
RETURN ON EQUITY (ROE) AVG 3Y
-33.09%
RETURN ON EQUITY (ROE) AVG 5Y
-32.11%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-34.12%
CURRENT VS 3Y AVG
-43.13%
CURRENT VS 5Y AVG
-47.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.92%
median of 594 covered companies
CURRENT VS SECTOR MEDIAN
-18.62%
vs the sector median at left
Nkarta, Inc.
Market Cap
$172.78M
Return on Equity (ROE)
-47.36%
TTM Avg
-35.31%
3Y Avg
-33.09%
5Y Avg
-32.11%
Market Cap
$173.76M
Return on Equity (ROE)
-54.27%
TTM Avg
-50.07%
3Y Avg
-62.91%
5Y Avg
-60.87%
Market Cap
$172.45M
Return on Equity (ROE)
-56.61%
TTM Avg
-75.88%
3Y Avg
-88.15%
5Y Avg
-30.55%
Market Cap
$174.58M
Return on Equity (ROE)
-116.42%
TTM Avg
-18.43%
3Y Avg
-136.68%
5Y Avg
-137.61%
Market Cap
$175.51M
Return on Equity (ROE)
-7104.24%
TTM Avg
-166.54%
3Y Avg
-137.65%
5Y Avg
-112.46%
Market Cap
$169.21M
Return on Equity (ROE)
-31.32%
TTM Avg
4.38%
3Y Avg
4.09%
5Y Avg
11.26%
Market Cap
$168.14M
Return on Equity (ROE)
3.51%
TTM Avg
-6.60%
3Y Avg
-9.04%
5Y Avg
-6.71%
Market Cap
$179.19M
Return on Equity (ROE)
-44.23%
TTM Avg
-36.61%
3Y Avg
-30.86%
5Y Avg
-42.66%
Market Cap
$180.06M
Return on Equity (ROE)
-19.01%
TTM Avg
-54.50%
3Y Avg
-75.60%
5Y Avg
-59.28%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | $172.78M | -47.36% | -35.31% | -33.09% | -32.11% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -54.27% | -50.07% | -62.91% | -60.87% |
| MediWound Ltd. (MDWD)vs › | $172.45M | -56.61% | -75.88% | -88.15% | -30.55% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.58M | -116.42% | -18.43% | -136.68% | -137.61% |
| Cue Biopharma, Inc. (CUE)vs › | $175.51M | -7104.24% | -166.54% | -137.65% | -112.46% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | -31.32% | 4.38% | 4.09% | 11.26% |
| OptimizeRx Corp. (OPRX)vs › | $168.14M | 3.51% | -6.60% | -9.04% | -6.71% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.19M | -44.23% | -36.61% | -30.86% | -42.66% |
| Journey Medical Corporation (DERM)vs › | $180.06M | -19.01% | -54.50% | -75.60% | -59.28% |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | -215.26% | -150.35% | 8.65% | -35.35% |
ROE
-47.4%
ROA
-34.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -47.36% |
| 2026-03-31 | -34.96% |
| 2025-12-31 | -33.33% |
| 2025-09-30 | -30.37% |
| 2025-06-30 | -30.54% |
| 2025-03-31 | -29.37% |
| 2024-12-31 | -26.67% |
| 2024-09-30 | -25.67% |
| 2024-06-30 | -23.81% |
| 2024-03-31 | -24.53% |
| 2023-12-31 | -43.00% |
| 2023-09-30 | -41.21% |
| 2023-06-30 | -39.32% |
| 2023-03-31 | -34.23% |
| 2022-12-31 | -30.58% |
| 2022-09-30 | -26.07% |
| 2022-06-30 | -23.29% |
| 2022-03-31 | -40.53% |
| 2021-12-31 | -34.30% |
| 2021-09-30 | -30.06% |
| 2021-06-30 | -25.14% |
| 2021-03-31 | -33.34% |
| 2020-12-31 | -28.44% |
| 2020-09-30 | -25.06% |
| 2020-03-31 | -102.21% |
